Wednesday, February 16, 2022

Baudax Bio (BXRX)
Adjusting price target for stock split and updated funding expectations

Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.

Gregory Aurand, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Board approved a 1:35 reverse split. A shareholder meeting held February 9th approved an amendment granting the Board of Directors authority to effect a reverse split. Last night the Board approved and filed a 1 for 35 reverse split, effective February 16, 2022. This split will help BXRX regain Nasdaq compliance.


New CDC proposal encourages non-opioid therapies.  Last updated in 2016, the CDC has opened a public comment 60-day period for updated guidelines. The updated guidelines remove hard limitations on opioid dosage but, given opioid side effects and addiction problems, continue to recommend non-opioid therapies, like ANJESO, whenever possible to treat chronic and acute pain …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.